FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1368-1378 October 28, 1999 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Figueras, J. PubMed Citation

In the United States, an estimated 20,000 new cases of liver and biliary tract cancer are diagnosed annually.¹ Biliary tract cancer is the second most common primary hepatobiliary cancer, after hepatocellular cancer. Approximately 7500 new cases of biliary tract cancer are diagnosed per year; about 5000 of these are gallbladder cancer, and between 2000 and 3000 are bile-duct cancers.¹ Biliary tract cancers have traditionally been divided into cancers of the gallbladder, the extrahepatic bile ducts, and the ampulla of Vater, whereas intrahepatic bile-duct cancers have been classified as primary liver cancers.² The term "cholangiocarcinoma" was originally intended to refer only . . . [Full Text of this Article]

Pathological Features

Risk Factors

Molecular Aspects

Diagnosis

Treatment and Survival

Surgery

Radiation

Chemotherapy

Other Palliative Treatments

Future Directions

Source Information

From the Mayo Clinic, Rochester, Minn.

Address reprint requests to Dr. de Groen at the Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905.

References

Related Letters:

Biliary Tract Cancers
Figueras J., Valls C., Jaurrieta E., de Groen P. C.
Extract | Full Text  
N Engl J Med 2000; 342:663-664, Mar 2, 2000. Correspondence

This article has been cited by other articles:

• Shi, C., Chandrasekaran, A., Thuluvath, P. J., Karikari, C., Argani, P., Goggins, M., Maitra, A., Eshleman, J. R. (2009). Ultrasensitive Detection of KRAS2 Mutations in Bile and Serum from Patients with Biliary Tract Carcinoma Using LigAmp Technology. J. Mol. Diagn. 11: 583-589 [Abstract] [Full Text]  
• Yamashita, Y.-i., Taketomi, A., Itoh, S., Harimoto, N., Tsujita, E., Sugimachi, K., Gion, T., Maehara, Y. (2009). Phase II Trial of Gemcitabine Combined with 5-fluorouracil and Cisplatin (GFP) Chemotherapy in Patients with Advanced Biliary Tree Cancers. Jpn J Clin Oncol 0: hyp119v1-hyp119 [Abstract] [Full Text]  
• Herberger, B., Berger, W., Puhalla, H., Schmid, K., Novak, S., Brandstetter, A., Pirker, C., Gruenberger, T., Filipits, M. (2009). Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Molecular Cancer Therapeutics 8: 1547-1556 [Abstract] [Full Text]  
• Eckel, F., Jelic, S., On behalf of the ESMO Guidelines Working Group, (2009). Biliary cancer: ESMO Clinical Recommendation for diagnosis, treatment and follow-up. Ann Oncol 20: iv46-iv48 [Full Text]  
• Shen, Y.-C., Hu, F.-C., Jeng, Y.-M., Chang, Y.-T., Lin, Z.-Z., Chang, M.-C., Hsu, C., Cheng, A.-L. (2009). Nuclear Overexpression of Mitotic Regulatory Proteins in Biliary Tract Cancer: Correlation with Clinicopathologic Features and Patient Survival. Cancer Epidemiol. Biomarkers Prev. 18: 417-423 [Abstract] [Full Text]  
• Randi, G., Malvezzi, M., Levi, F., Ferlay, J., Negri, E., Franceschi, S., La Vecchia, C. (2009). Epidemiology of biliary tract cancers: an update. Ann Oncol 20: 146-159 [Abstract] [Full Text]  
• Sainani, N. I., Catalano, O. A., Holalkere, N.-S., Zhu, A. X., Hahn, P. F., Sahani, D. V. (2008). Cholangiocarcinoma: Current and Novel Imaging Techniques1. RadioGraphics 28: 1263-1287 [Abstract] [Full Text]  
• Mott, J. L., Bronk, S. F., Mesa, R. A., Kaufmann, S. H., Gores, G. J. (2008). BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Molecular Cancer Therapeutics 7: 2339-2347 [Abstract] [Full Text]  
• Andreotti, G., Chen, J., Gao, Y.-T., Rashid, A., Chen, B. E., Rosenberg, P., Sakoda, L. C., Deng, J., Shen, M.-C., Wang, B.-S., Han, T.-Q., Zhang, B.-H., Yeager, M., Welch, R., Chanock, S., Fraumeni, J. F. Jr., Hsing, A. W. (2008). Polymorphisms of Genes in the Lipid Metabolism Pathway and Risk of Biliary Tract Cancers and Stones: A Population-Based Case-Control Study in Shanghai, China. Cancer Epidemiol. Biomarkers Prev. 17: 525-534 [Abstract] [Full Text]  
• Khan, S A, Miras, A, Pelling, M, Taylor-Robinson, S D (2007). Cholangiocarcinoma and its management. Gut 56: 1755-1756 [Full Text]  
• Yonemoto, N., Furuse, J., Okusaka, T., Yamao, K., Funakoshi, A., Ohkawa, S., Boku, N., Tanaka, K., Nagase, M., Saisho, H., Sato, T. (2007). A Multi-center Retrospective Analysis of Survival Benefits of Chemotherapy for Unresectable Biliary Tract Cancer. Jpn J Clin Oncol 37: 843-851 [Abstract] [Full Text]  
• Herberger, B., Puhalla, H., Lehnert, M., Wrba, F., Novak, S., Brandstetter, A., Gruenberger, B., Gruenberger, T., Pirker, R., Filipits, M. (2007). Activated Mammalian Target of Rapamycin Is an Adverse Prognostic Factor in Patients with Biliary Tract Adenocarcinoma. Clin. Cancer Res. 13: 4795-4799 [Abstract] [Full Text]  
• Matull, W.-R., Khan, S. A., Pereira, S. P. (2007). Re: Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States. JNCI J Natl Cancer Inst 99: 407-407 [Full Text]  
• Welzel, T. M., McGlynn, K. A., Hsing, A. W., O'Brien, T. R., Pfeiffer, R. M. (2007). Response: Re: Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States. JNCI J Natl Cancer Inst 99: 407-408 [Full Text]  
• Slattery, J. M., Sahani, D. V. (2006). What Is the Current State-of-the-Art Imaging for Detection and Staging of Cholangiocarcinoma?. The Oncologist 11: 913-922 [Abstract] [Full Text]  
• Welzel, T. M., McGlynn, K. A., Hsing, A. W., O'Brien, T. R., Pfeiffer, R. M. (2006). Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States.. JNCI J Natl Cancer Inst 98: 873-875 [Abstract] [Full Text]  
• Lee, H. Y., Kim, S. H., Lee, J. M., Kim, S.-W., Jang, J.-Y., Han, J. K., Choi, B. I. (2006). Preoperative Assessment of Resectability of Hepatic Hilar Cholangiocarcinoma: Combined CT and Cholangiography with Revised Criteria. Radiology 239: 113-121 [Abstract] [Full Text]  
• Karikari, C. A., Mullendore, M., Eshleman, J. R., Argani, P., Leoni, L. M., Chattopadhyay, S., Hidalgo, M., Maitra, A. (2005). Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. Molecular Cancer Therapeutics 4: 1860-1866 [Abstract] [Full Text]  
• Reinhardt, M. J., Strunk, H., Gerhardt, T., Roedel, R., Jaeger, U., Bucerius, J., Sauerbruch, T., Biersack, H.-J., Dumoulin, F. L. (2005). Detection of Klatskin's Tumor in Extrahepatic Bile Duct Strictures Using Delayed 18F-FDG PET/CT: Preliminary Results for 22 Patient Studies. JNM 46: 1158-1163 [Abstract] [Full Text]  
• Knox, J. J., Hedley, D., Oza, A., Feld, R., Siu, L. L., Chen, E., Nematollahi, M., Pond, G. R., Zhang, J., Moore, M. J. (2005). Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. JCO 23: 2332-2338 [Abstract] [Full Text]  
• Park, J.-S., Oh, S.-Y., Kim, S.-H., Kwon, H.-C., Kim, J.-S., Jin-Kim, H., Kim, Y.-H. (2005). Single-agent Gemcitabine in the Treatment of Advanced Biliary Tract Cancers: a Phase II Study. Jpn J Clin Oncol 35: 68-73 [Abstract] [Full Text]  
• Kristiansen, T. Z., Bunkenborg, J., Gronborg, M., Molina, H., Thuluvath, P. J., Argani, P., Goggins, M. G., Maitra, A., Pandey, A. (2004). A Proteomic Analysis of Human Bile. Mol. Cell. Proteomics 3: 715-728 [Abstract] [Full Text]  
• Rea, D. J., Munoz-Juarez, M., Farnell, M. B., Donohue, J. H., Que, F. G., Crownhart, B., Larson, D., Nagorney, D. M. (2004). Major Hepatic Resection for Hilar Cholangiocarcinoma: Analysis of 46 Patients. Arch Surg 139: 514-525 [Abstract] [Full Text]  
• Yeh, C.-N., Maitra, A., Lee, K.-F., Jan, Y.-Y., Chen, M.-F. (2004). Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 25: 631-636 [Abstract] [Full Text]  
• Kornek, G. V., Schuell, B., Laengle, F., Gruenberger, T., Penz, M., Karall, K., Depisch, D., Lang, F., Scheithauer, W. (2004). Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 15: 478-483 [Abstract] [Full Text]  
• Nakajima, T., Takayama, T., Miyanishi, K., Nobuoka, A., Hayashi, T., Abe, T., Kato, J., Sakon, K., Naniwa, Y., Tanabe, H., Niitsu, Y. (2003). Reversal of Multiple Drug Resistance in Cholangiocarcinoma by the Glutathione S-Transferase-{pi}-Specific Inhibitor O1-Hexadecyl-{gamma}-glutamyl-S-benzylcysteinyl-D-phenylglycine Ethylester. J. Pharmacol. Exp. Ther. 306: 861-869 [Abstract] [Full Text]  
• Hansel, D. E., Rahman, A., Hidalgo, M., Thuluvath, P. J., Lillemoe, K. D., Shulick, R., Ku, J.-L., Park, J.-G., Miyazaki, K., Ashfaq, R., Wistuba, I. I., Varma, R., Hawthorne, L., Geradts, J., Argani, P., Maitra, A. (2003). Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology. Am. J. Pathol. 163: 217-229 [Abstract] [Full Text]  
• Khan, S A, Carmichael, P L, Taylor-Robinson, S D, Habib, N, Thomas, H C (2003). DNA adducts, detected by 32P postlabelling, in human cholangiocarcinoma. Gut 52: 586-591 [Abstract] [Full Text]  
• Lai, G.-H., Zhang, Z., Sirica, A. E. (2003). Celecoxib Acts in a Cyclooxygenase-2-independent Manner and in Synergy with Emodin to Suppress Rat Cholangiocarcinoma Growth in Vitro through a Mechanism Involving Enhanced Akt Inactivation and Increased Activation of Caspases-9 and -3. Molecular Cancer Therapeutics 2: 265-271 [Abstract] [Full Text]  
• Schrumpf, E, Boberg, K M (2003). Hepatic and extrahepatic malignancies and primary sclerosing cholangitis. Gut 52: 165-165 [Full Text]  
• Makower, D., Rozenblit, A., Kaufman, H., Edelman, M., Lane, M. E., Zwiebel, J., Haynes, H., Wadler, S. (2003). Phase II Clinical Trial of Intralesional Administration of the Oncolytic Adenovirus ONYX-015 in Patients with Hepatobiliary Tumors with Correlative p53 Studies. Clin. Cancer Res. 9: 693-702 [Abstract] [Full Text]  
• Khan, S A, Davidson, B R, Goldin, R, Pereira, S P, Rosenberg, W M C, Taylor-Robinson, S D, Thillainayagam, A V, Thomas, H C, Thursz, M R, Wasan, H (2002). Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51: vi1-9 [Full Text]  
• Baron, T. H., Fleischer, D. E. (2002). Past, Present, and Future of Endoscopic Retrograde Cholangiopancreatography: Perspectives on the National Institutes of Health Consensus Conference. Mayo Clin Proc. 77: 407-412  
• Fiorentino, M., Altimari, A., D'Errico, A., Gabusi, E., Chieco, P., Masetti, M., Grigioni, W. F. (2001). Low p27 Expression Is an Independent Predictor of Survival for Patients with Either Hilar or Peripheral Intrahepatic Cholangiocarcinoma. Clin. Cancer Res. 7: 3994-3999 [Abstract] [Full Text]  
• Fonck, C., Chauveau, D., Gagnadoux, M.-F., Pirson, Y., Grunfeld, J.-P. (2001). Autosomal recessive polycystic kidney disease in adulthood. Nephrol Dial Transplant 16: 1648-1652 [Abstract] [Full Text]  
• Hocqueloux, L., Molina, J.-M., Gervais, A. (2000). Cholangiocarcinoma and AIDS-Related Sclerosing Cholangitis. ANN INTERN MED 132: 1006-1007 [Full Text]  
• Figueras, J., Valls, C., Jaurrieta, E., de Groen, P. C. (2000). Biliary Tract Cancers. NEJM 342: 663-664 [Full Text]